Celltrion Receives Final Approval for Humira Biosimilar Sales in Europe
[Asia Economy Reporter Ji Yeon-jin] Celltrion announced on the 15th that its biosimilar of Humira, a treatment for rheumatoid arthritis and other conditions, Uplyma (CT-P17), obtained final marketing authorization from the European Commission (EC) on the 11th (local time).
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- "To Get Revenge on Ex-Girlfriend" US McDonald's Manager Spits on French Fries
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Uplyma (CT-P17) is the first biosimilar of Humira developed in a high-concentration formulation, and its marketability was enhanced by removing citrate, which can cause pain to patients. Sales in Europe will be supplied to 30 European Union countries through Celltrion Healthcare, which is responsible for overseas marketing and distribution of Celltrion products.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
